Day: May 6, 2021

EBITDA1 of $392 million on Sales of $849 millionNet Cash Position and Available Liquidity of $944 million BURNABY, British Columbia, May 06, 2021 (GLOBE NEWSWIRE) — INTERFOR CORPORATION (“Interfor” or the “Company”) (TSX: IFP) recorded Net earnings in Q1’21 of $264.5 million, or $4.01 per share, compared to $149.1 million, or $2.24 per share in Q4’20 and $6.3 million, or $0.09 per share in Q1’20. Adjusted net earnings in Q1’21 was $270.6 million compared to $164.7 million in Q4’20 and $0.7 million in Q1’20. Adjusted EBITDA was a record $392.1 million on sales of $849.3 million in Q1’21 versus $248.6 million on sales of $662.3 million in Q4’20. Notable items in the quarter:Strong Free Cash Flow GenerationInterfor generated $377.7 million of cash flow from operations before changes in working capital, or $5.73 per share. Working...

Acquisition of Zikani Therapeutics, Ribosomal Modulation Company; Combined Company Advancing Ribosomal RNA-Targeted Genetic Therapies Additional Treatment Arm Added to Ongoing Phase 2 Clinical Studies for Cystic Fibrosis (CF) Cystic Fibrosis Foundation (CF Foundation) Increases Clinical Trial Funding to Include Europe and Israel ELX-02 Phase 1 Results Published in Multiple Scientific Journals WALTHAM, Mass., May 06, 2021 (GLOBE NEWSWIRE) — Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today reported its financial results for the three months ended March 31, 2021 and provided a business update. “The beginning of 2021 has been transformative for Eloxx and was extremely important in laying the groundwork for the future success of ELX-02, our candidate for cystic...

BELTSVILLE, Md., May 06, 2021 (GLOBE NEWSWIRE) — NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today reported first quarter 2021 financial results and provided a business update. “We are highly focused on advancing our three clinical programs and broadening our pipeline of novel immunomedicines this year. We are committed to continuing to evaluate NC318 in multiple indications in our Phase 2 monotherapy trial as well as the Phase 2 investigator-initiated clinical trial at Yale University that recently commenced,” said Michael Richman, NextCure’s president and chief executive officer. “The NC410 program continues to advance and we will be sharing a trial in progress poster at...

HOUSTON, May 06, 2021 (GLOBE NEWSWIRE) — Epsilon Energy Ltd. (“Epsilon” or the “Company”) (NASDAQ: EPSN) today reported first quarter 2021 financial and operating results and material subsequent events following the end of the quarter through the date of this release.Net cash provided by operations of $5.6 million for the three months ended March 31, 2021, with free cash flow (FCF) of $5.1 million for the same period.Realized gas prices of $2.57/Mcf, (excluding hedges) and $2.61/Mcf (including hedges) for the three months ended March 31, 2021.During the first three months of 2021 the company returned a total of $0.5 million to shareholders through share repurchases representing a reduction of 0.5% of outstanding shares from December 31, 2020.Marcellus net revenue interest (NRI) gas production averaged 26.8 MMcf/d (Working...

CANTON, Mass., May 06, 2021 (GLOBE NEWSWIRE) — Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that the latest advanced wound care research on its PuraPly® AM, Affinity®, Apligraf®, and Nushield® product lines will be showcased at the 2021 Symposium on Advanced Wound Care (SAWC) Spring | Wound Healing Society Virtual Experience, held May 10-14. As a Platinum Sponsor for this year’s conference, Organogenesis will present an Innovation Theater titled “Clinical Evidence Outlines the Need for Early Advanced Standard of Care with Real-world Chronic Case Reviews” on Friday, May 14 from 12:20 –1:20 p.m. ET. Led by...

WINNIPEG, Manitoba, May 06, 2021 (GLOBE NEWSWIRE) — (TSX: NFI, OTC: NFYEF) The board of directors (the “Board”) of NFI Group Inc. (“NFI”), a leader in zero-emission electric mobility solutions, is pleased to announce that the ten nominees listed in the management information circular dated March 19, 2021, were elected as Directors of NFI. The detailed results of the vote for the election of Directors held at the annual meeting of shareholders (the “Meeting”) held today are set out below.Name of Nominee Votes For % For Votes Withheld % WithheldPhyllis Cochran 40,834,109 99.64 147,132 0.36Larry Edwards 40,274,666 98.28 706,575 1.72Adam Gray 40,576,867 99.01 404,374 0.99Krystyna Hoeg 40,678,405 99.26 302,836 0.74John Marinucci 40,815,391 99.60 165,850 0.40Paulo Cezar da Silva Nunes 39,684,666 96.84 1,296,575 3.16Colin...

New project awards and contract renewals total $176 million during the first four months of 2021 CALGARY, Alberta, May 06, 2021 (GLOBE NEWSWIRE) — ClearStream Energy Services Inc. (“ClearStream” or the “Company”) (TSX: CSM) today announced its results for the three months ended March 31, 2021. All amounts are in Canadian dollars and expressed in thousands of dollars unless otherwise noted. “EBITDAS” and “Adjusted EBITDAS” are not standard measures under IFRS. Please refer to the Advisory regarding Non-Standard Measures at the end of this press release for a description of these items and limitations of their use. “We delivered a solid first quarter in 2021 as the recovery that commenced in the second half of 2020 extended into the first quarter of 2021. We continued to see our business stabilize as revenues in the first...

LOS ANGELES, May 06, 2021 (GLOBE NEWSWIRE) — Barfresh Food Group, Inc. (the “Company” or “Barfresh”) (OTCQB: BRFH), a provider of frozen, ready-to-blend and ready-to-drink beverages, announced that it will host a business update call on Monday, May 17, 2021, at 1:30 pm Pacific Time (4:30 pm Eastern Time). Listeners can dial (877) 407-4018 in North America, and international listeners can dial (201) 689-8471. A telephonic playback will be available approximately two hours after the call concludes and will be available through Monday, May 31, 2021. Listeners in North America can dial (844) 512-2921, and international listeners can dial (412) 317-6671. Passcode is 13719382. Interested parties may also listen to a simultaneous webcast of the conference call by logging onto the company’s website at www.barfresh.com in the Investors-Presentations...

Webcast Today at 4:30 pm Eastern Time SOUTH SAN FRANCISCO, May 06, 2021 (GLOBE NEWSWIRE) — In a release issued under the same headline on Thursday, May 6th by Tricida, Inc. (Nasdaq: TCDA), please note that the first and second bullets of the “Upcoming Milestones” should have been combined into one bullet. The corrected release follows: Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its investigational drug candidate, veverimer, a non-absorbed, orally-administered polymer designed to treat metabolic acidosis and slow CKD progression in patients with chronic kidney disease (CKD), announced today financial results for the three months ended March 31, 2021 and provided an update on key initiatives. Recent EventsTricida continues to execute on recruitment and...